GL1X · GenesisL1 explorer

Research workbench

SARS-cov-2 receptor binding domain in complex with AB17

Analyse SARS-cov-2 receptor binding domain in complex with AB17 in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
7TE1
Type
protein
Length
1,178 residues
Chains
6
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
AB17 heavy chain; AB17 light chain; Spike protein S1
UniProt
P0DTC2
Pockets
12 · best druggability 0.74

Structure

x-ray diffraction · 6 distinct chains · 7% helix, 41% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
CAB17 heavy chainprotein2091% helix, 50% strand—
FAB17 light chainprotein2106% helix, 46% strand—
HAB17 heavy chainprotein2061% helix, 45% strand—
LAB17 light chainprotein1965% helix, 46% strand—
DSpike protein S1protein17018% helix, 25% strandP0DTC2
ESpike protein S1protein18716% helix, 28% strandP0DTC2

Pockets

12 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
111500.740.77107empty
26620.680.7766empty
3680.580.8924empty
41060.490.8120empty
51150.440.7818empty

Interfaces

10 interfaces between chains.

  • C–F · 1949 Ų buried · 18 hydrogen bonds · protein-protein
  • H–L · 1838 Ų buried · 14 hydrogen bonds · protein-protein
  • H–D · 680 Ų buried · 10 hydrogen bonds · protein-protein
  • C–E · 597 Ų buried · 4 hydrogen bonds · protein-protein
  • L–D · 539 Ų buried · 7 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 14 disulfide (disulfide).

Compared structures

  • 7TE1 · SARS-CoV-2 Receptor Binding Domain in Complex with Ab17 · the same entry in another collection · chain H against H, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.